Announcement
N4 Pharma PLC : Double siRNA Testing Update
RNS Number : 6141B
N4 Pharma PLC
04 October 2022
|
|
|
4 October 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Double siRNA Testing Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec® loaded with two small interfering RNA (siRNA) probes.
On 14 September 2022, the Company announced a strategic update highlighting its intention to focus its further development work on multiple loaded siRNA on Nuvec®.
T he Company has now completed initial in vitro testing of Nuvec® loaded with two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2 ) at the same time. The siRNA probes were loaded onto Nuvec® in equal amounts, at a concentration previously shown to be active. Testing demonstrated that both siRNA probes when loaded onto Nuvec® were able to significantly silence their respective targets.
Nigel Theobald, Chief Executive Officer of the Company, commented :
"Showing that Nuvec® loaded with two generic siRNA probes still achieves significant silencing of their respective genes is validation for us to now begin the further work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer model.
"Achieving the initial successful testing of Nuvec ® with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking ."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.
Enquiries:
|
N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director |
Via IFC Advisory |
|
|
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) |
Tel: + 44 (0)20 3470 0470 |
|
|
|
|
IFC Advisory Limited Financial PR Graham Herring Zach Cohen |
Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCMJBATMTJMBTT
;